Firebrick Pharma (FRE) Short Interest
Firebrick Pharma (ASX:FRE) had 0.01% of shares reported as short positions as of 29 June 2026, representing 19,206 shares. Firebrick Pharma operates in the Pharmaceuticals, Biotechnology & Life Sciences industry. Source: ASIC short position report (T+4 delay).
Source: official ASIC short position report, T+4 delay. Methodology · Disclaimer — not financial advice.
Firebrick Pharma
Firebrick Pharma is a pharmaceutical development and manufacturing company focused on developing and commercializing nasal sprays based on povidone-iodine (PVP-I). Their lead product, Nasodine Nasal Spray, is intended as a treatment for the common cold. The company aims to bring Nasodine to the global market.
Short position
Firebrick Pharma (ASX:FRE) has 0.01% of its shares on issue reported as short positions as of 29 June 2026, or about 19,206 shares. Over the past 30 days that figure has been broadly flat, and over 90 days it has been broadly flat. FRE is classified in the Pharmaceuticals, Biotechnology & Life Sciences industry. All figures come from official ASIC short position reports, published with a four trading-day (T+4) delay.
Weekly context: The 10 most shorted ASX stocks — Week 34, 2026.
Price & short interest
Toggle series, zoom, and compare · ASIC daily, T+4FRE intelligence dossier
Public-source evidence for this company, with industry drill-up links.
- Tax paid and taxable income records
- Government contracts and public money
- Emissions and trade exposure
- Political donations and lobbying links
Short interest history & FAQ
Company
AI-generated research profile of Firebrick Pharma
About
website
address
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Be the first to discuss FRE
Start a research thread or post the first pulse update